AIM
PPBT

ARK Investment Management’s Purple Biotech PPBT Stock Holding History

ARK Investment Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,312
Closed -$2.58M – 377
2021
Q4 		$2.58M Sell
3,312
-368
-10% -$313K 0.01% 224
2021
Q3 		$3.37M Buy
+3,680
New +$3.56M 0.01% 222

Other funds holding PPBT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WTB
Washington Trust Bank Spokane, Washington $1.36B AUM 21.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ARK Investment Management's PPBT Position: Q1 2022 in Review

ARK Investment Management sold out of Purple Biotech (PPBT) in Q1 2022, closing a stake of 3,312 shares — an estimated $2.58M sold.

ARK Investment Management first reported a position in PPBT in Q3 2021 and held it in 2 quarters. The position peaked at $3.37M in Q3 2021. 12 funds tracked by Wall St. Rank hold PPBT as of Q1 2022.

  • ARK Investment Management reported no remaining Purple Biotech position as of Q1 2022 after selling out during the quarter.
  • ARK Investment Management sold 3,312 Purple Biotech shares in Q1 2022, an estimated $2.58M.
  • ARK Investment Management first reported a position in Purple Biotech in Q3 2021 and held it in 2 quarters.
  • ARK Investment Management's Purple Biotech position peaked at $3.37M in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2022.

Based on ARK Investment Management's 13F filing for Q1 2022, filed 19 Apr 2022.